Tetraphase Pharmaceuticals, Inc. (TTPH)

[Schnauzer1]

If you listen to Aug. 24 investor conference at TTPH investor relations you will discover that Intra-abdominal infection P3 (cIAI) is to starts in fourth quarter. It is expected that trial will take 12 months. This is the Pivital trial for drug approval (second successful trial). Additionally, a cUTI P3 will start soon for label extension, expecting to take year and half. Important take away is the prior failed cUTI has been created to food effect on oral formulation. Also, Ervacycline is becoming more valuable as more bad bugs stories are suggesting run away ptroblem, with no other P3 drug in pipeline by other drug companies with same effectiveness as Ervacycline. Cash position is good, with enough to carry through all existing trial activity. Truly a remarkable buying opportunity. Be ready for long term hold before any substantial value increase (12 months). Although ...